Cart
sales@molnova.com
Poziotinib
CAS No. 1092364-38-9
Poziotinib( HM781-36B | NOV120101 )
Catalog No. M10347 CAS No. 1092364-38-9
Poziotinib (HM781-36B, NOV120101) is an irreversible pan-HER inhibitor with IC50 of 3.2/5.3 nM/23.5 nM for HER1/HER2/HER4.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 65 | In Stock |
|
| 5MG | 61 | In Stock |
|
| 10MG | 93 | In Stock |
|
| 25MG | 186 | In Stock |
|
| 50MG | 323 | In Stock |
|
| 100MG | 508 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePoziotinib
-
NoteResearch use only, not for human use.
-
Brief DescriptionPoziotinib (HM781-36B, NOV120101) is an irreversible pan-HER inhibitor with IC50 of 3.2/5.3 nM/23.5 nM for HER1/HER2/HER4.
-
DescriptionPoziotinib (HM781-36B, NOV120101) is an irreversible pan-HER inhibitor with IC50 of 3.2/5.3 nM/23.5 nM for HER1/HER2/HER4; inhibits phosphorylation of HER family and downstream signaling molecules, and induced apoptosis and G1 arrest; exerts synergistic effects with chemotherapeutic agents.Breast Cancer Phase 2 Clinical.
-
In Vitro——
-
In Vivo——
-
SynonymsHM781-36B | NOV120101
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorHER1|HER2|HER4
-
Research AreaCancer
-
IndicationBreast Cancer
Chemical Information
-
CAS Number1092364-38-9
-
Formula Weight491.3423
-
Molecular FormulaC23H21Cl2FN4O3
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESC=CC(N1CCC(OC2=CC3=C(NC4=CC=C(Cl)C(Cl)=C4F)N=CN=C3C=C2OC)CC1)=O
-
Chemical Name2-Propen-1-one, 1-[4-[[4-[(3,4-dichloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-piperidinyl]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Nam HJ, et al. Cancer Lett. 2011 Mar 28;302(2):155-65.
2. Cha MY, et al. Int J Cancer. 2012 May 15;130(10):2445-54.
3. Kim HJ, et al. Anticancer Drugs. 2012 Mar;23(3):288-97.
molnova catalog
related products
-
Rezivertinib
Rezivertinib (BPI-7711) is an orally available, selective and potent inhibitor of tyrosine kinase (EGFR) with antitumor activity for central nervous system disorders.
-
Gefitinib hydrochlor...
A potent, selective, orally active EGFR inhibitor with IC50 of 23 nM.
-
AG 99
AG-99 is an inhibitor of EGFR kinase (IC50: 10 μM in the human epidermoid carcinoma cell line A431).
